Pharmacological evaluation of anti-leishmanial activity by in vivo nitric oxide modulation in Balb/c mice infected with Leishmania major MRHO/IR/75/ER: an Iranian strain of cutaneous leishmaniasis.
Cutaneous leishmaniasis with a variation in its clinical signs is still one of the health problems in the world, region and Iran. Immune responses against leishmania consist of cytokines, immune cells and mediators. Macrophages participate actively in the inflammatory response by releasing chemokines and mediators including nitric oxide (NO) and reactive oxygen and nitrogen intermediates. This study investigates whether NO had anti-leishmanial effects and/or mediated pathology in mice infected with Leishmania major MRHO/IR/75/ER (IR/75). NO inducer lipopolysaccharide (LPS) and NO donor S-nitrosoglutathione (SNOG) were used for their ability to increase RNI and to modify leishmania infection in susceptible Balb/c mice, in order to evaluate the effects of NO production on size and lesion macroscopy, delay of lesion formation and proliferation of amastigotes inside macrophages. Liver, spleen and lymph nodes were also studied as target organs to detect amastigotes. In addition to plasma, liver and spleen suspensions were investigated for NO induction by using Griess microassay. Statistical analysis of data revealed an association between increases in NO level with the pathology of disease in Balb/c mice infected with L. major IR/75. The survival of leishmania parasite inside the macrophages and its proliferation was affected by LPS and SNOG-treatments. An inconsistent relationship was evident between the NO modulation and pathological changes in treated Balb/c mice infected with L. major IR/75.
Nahrevanian
Hossein
H
Department of Parasitology, Pasteur Institute of Iran, Tehran, Islamic Republic of Iran. mobcghn@yahoo.co.uk
Farahmand
Mahin
M
Aghighi
Zohreh
Z
Assmar
Mehdi
M
Amirkhani
Aref
A
D000818:Animals; D005260:Female; D018320:Leishmania major / Q000187:drug effects* / Q000276:immunology; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000276:immunology* / Q000469:parasitology; D008070:Lipopolysaccharides / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000378:metabolism / Q000469:parasitology; D008198:Lymph Nodes / Q000469:parasitology; D008264:Macrophages / Q000276:immunology / Q000378:metabolism / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D009569:Nitric Oxide / Q000096:biosynthesis / Q000276:immunology*; D020030:Nitric Oxide Donors / Q000494:pharmacology* / Q000627:therapeutic use; D026361:Reactive Nitrogen Species / Q000096:biosynthesis / Q000097:blood; D026422:S-Nitrosoglutathione / Q000494:pharmacology* / Q000627:therapeutic use; D012475:Salmonella; D013154:Spleen / Q000378:metabolism / Q000469:parasitology
D008070:Lipopolysaccharides; D020030:Nitric Oxide Donors; D026361:Reactive Nitrogen Species; D009569:Nitric Oxide; D026422:S-Nitrosoglutathione